New hope for ovarian cancer: targeted drug combo may be gentler than standard chemo
NCT ID NCT07285941
First seen Jan 10, 2026 · Last updated May 01, 2026 · Updated 18 times
Summary
This study tests a new drug combination (distamab vedotin plus carboplatin) in 20 people with advanced ovarian cancer that has a specific protein called HER2. The goal is to see if this combo works better and causes fewer side effects than the usual chemotherapy. Participants must have had surgery and not received chemo before.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhe Jiang Cancer Hospital
RECRUITINGZhejiang, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.